Share This Author
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.
GDC-0449, an orally active small molecule that targets the hedgehog pathway, appears to have antitumor activity in locally advanced or metastatic basal-cell carcinoma.
Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors
GDC-0449 has an acceptable safety profile and encouraging anti-tumor activity in advanced BCC and medulloblastoma, and evidence of GLI1 down-modulation was observed in noninvolved skin.
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.
Safety, pharmacokinetics, RNAi mechanism of action, and clinical activity with a novel LNP-formulated RNAi therapeutic in patients with cancer are shown, providing proof-of-concept for RNAi therapeutics in humans and the basis for further development in cancer.
Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
miR-1254 and miR-574-5p: Serum-Based microRNA Biomarkers for Early-Stage Non-small Cell Lung Cancer
- Kristen M. Foss, Chao Sima, D. Ugolini, M. Neri, Kristi E. Allen, G. Weiss
- Biology, MedicineJournal of thoracic oncology : official…
- 1 March 2011
Serum miRNAs are differentially expressed between patients with early-stage NSCLC and controls, and the utility of miR-1254 andmiR-574-5p serum-based biomarkers as minimally invasive screening and triage tools for subsequent diagnostic evaluation warrants additional validation.
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.
Treating tenosynovial giant-cell tumors with PLX3397 resulted in a prolonged regression in tumor volume in most patients, and the most common adverse events included fatigue, change in hair color, nausea, dysgeusia, and periorbital edema.
STAT3 Is Activated by JAK2 Independent of Key Oncogenic Driver Mutations in Non-Small Cell Lung Carcinoma
- B. Looyenga, Danielle Hutchings, I. Cherni, C. Kingsley, G. Weiss, J. MacKeigan
- Biology, ChemistryPloS one
- 2 February 2012
It is demonstrated that JAK2/STAT3 signaling operates independent of known driver mutations in NSCLC and plays critical roles in tumor cell behavior that may not be effectively inhibited by drugs that selectively target these driver mutations.
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
- A. Patnaik, L. Appleman, R. Ramanathan
- Medicine, BiologyAnnals of oncology : official journal of the…
- 26 September 2016
Copanlisib was well tolerated with a manageable safety profile, with anti-tumor activity in both advanced solid tumors and hematological malignancies, in patients with advancedsolid tumors or non-Hodgkin's lymphoma.
EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines.
- G. Weiss, L. Bemis, W. Franklin
- Biology, MedicineAnnals of oncology : official journal of the…
- 1 June 2008
Identifying microRNA regulators of oncogenes could have far-reaching implications for lung cancer patients including improving patient selection for targeted agents, development of novel therapeutics, or development as early biomarkers of disease.